250 related articles for article (PubMed ID: 36389657)
21. Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death.
Logan BR; Fu D; Howard A; Fei M; Kou J; Little MR; Adom D; Mohamed FA; Blazar BR; Gafken PR; Paczesny S
J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526081
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers in chronic graft-versus-host disease: quo vadis?
Wolff D; Greinix H; Lee SJ; Gooley T; Paczesny S; Pavletic S; Hakim F; Malard F; Jagasia M; Lawitschka A; Hansen JA; Pulanic D; Holler E; Dickinson A; Weissinger E; Edinger M; Sarantopoulos S; Schultz KR
Bone Marrow Transplant; 2018 Jul; 53(7):832-837. PubMed ID: 29367715
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis.
Goklemez S; Im AP; Cao L; Pirsl F; Steinberg SM; Curtis LM; Mitchell SA; Cowen EW; Baruffaldi J; Rose J; Mays J; Ostojic A; Holtzman NG; Hakim FT; Pavletic SZ
Am J Hematol; 2020 Apr; 95(4):387-394. PubMed ID: 31903638
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria.
Yang AH; Han MAT; Samala N; Rizvi BS; Marchalik R; Etzion O; Wright EC; Cao L; Hakim FT; Jones E; Kapuria D; Hickstein DD; Fowler D; Kanakry JA; Kanakry CG; Kleiner DE; Koh C; Pavletic SZ; Heller T
Transplant Cell Ther; 2022 Nov; 28(11):747.e1-747.e10. PubMed ID: 35878742
[TBL] [Abstract][Full Text] [Related]
25. Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease.
Lynch Kelly D; Farhadfar N; Starkweather A; Garrett TJ; Yao Y; Wingard JR; Mahmud I; Menzies V; Patel P; Alabasi KM; Lyon D
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1803-1810. PubMed ID: 32592859
[TBL] [Abstract][Full Text] [Related]
26. Evolving concepts in prognostic scoring of chronic GvHD.
Lazaryan A; Arora M
Bone Marrow Transplant; 2017 Oct; 52(10):1361-1366. PubMed ID: 28346419
[TBL] [Abstract][Full Text] [Related]
27. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ; Wolff D; Kitko C; Koreth J; Inamoto Y; Jagasia M; Pidala J; Olivieri A; Martin PJ; Przepiorka D; Pusic I; Dignan F; Mitchell SA; Lawitschka A; Jacobsohn D; Hall AM; Flowers ME; Schultz KR; Vogelsang G; Pavletic S
Biol Blood Marrow Transplant; 2015 Jun; 21(6):984-99. PubMed ID: 25796139
[TBL] [Abstract][Full Text] [Related]
28. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
29. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
[TBL] [Abstract][Full Text] [Related]
30. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia.
Kuzmina Z; Greinix HT; Weigl R; Körmöczi U; Rottal A; Frantal S; Eder S; Pickl WF
Blood; 2011 Feb; 117(7):2265-74. PubMed ID: 21063025
[TBL] [Abstract][Full Text] [Related]
31. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of NIH consensus criteria for chronic graft-versus-host disease.
Cho BS; Min CK; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
Leukemia; 2009 Jan; 23(1):78-84. PubMed ID: 18830253
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.
Kuzmina Z; Gounden V; Curtis L; Avila D; Rnp TT; Baruffaldi J; Cowen EW; Naik HB; Hasni SA; Mays JW; Mitchell S; Baird K; Steinberg SM; Pavletic SZ
Am J Hematol; 2015 Feb; 90(2):114-9. PubMed ID: 25363867
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic response of oral chronic graft-versus-host disease to topical corticosteroids according to the 2014 National Institutes of Health (USA) consensus criteria.
Siripornkitti W; Pengpis N; Chanswangphuwana C; Prueksrisakul T
Med Oral Patol Oral Cir Bucal; 2024 Mar; 29(2):e219-e226. PubMed ID: 37823294
[TBL] [Abstract][Full Text] [Related]
35. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.
Herzberg PY; Heussner P; Mumm FH; Horak M; Hilgendorf I; von Harsdorf S; Hemmati P; Rieger K; Greinix H; Freund M; Lee SJ; Holler E; Wolff D
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1707-17. PubMed ID: 20541028
[TBL] [Abstract][Full Text] [Related]
36. Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?
Perić Z; Desnica L; Duraković N; Ostojić A; Pulanić D; Serventi-Seiwerth R; Prenc E; Basak G; Vrhovac R; Pavletic SZ; Nemet D
Croat Med J; 2016 Feb; 57(1):6-15. PubMed ID: 26935610
[TBL] [Abstract][Full Text] [Related]
37. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
[TBL] [Abstract][Full Text] [Related]
38. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
39. Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients.
Kerep AZ; Broome J; Pirsl F; Curtis LM; Steinberg SM; Mitchell SA; Cowen EW; Pichard DC; Joe GO; Comis LE; Mays JW; Datiles MB; Stratton P; Zolton J; Berger A; Hendricks J; Kenyon M; Baruffaldi J; Titarenko I; Pulanic D; Baird K; Fowler DH; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2019 Jan; 54(1):76-84. PubMed ID: 30089900
[TBL] [Abstract][Full Text] [Related]
40. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
